Cristina S.
- Country
- Spain
- Department
- Oncologia
Research Overview
- Phase I Study of XL092 Monotherapy and Combination Therapy in Advanced Solid Tumors: ccRCC, nccRCC, HR+ BC, mCRPC, and CRC
- Phase 1 Evaluation of AB521 Monotherapy and Combination Therapies in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors
- Evaluation of RO7566802 Monotherapy and Combination with Atezolizumab in Locally Advanced or Metastatic Solid Tumor Malignancies
Data & Insights
Has run more than one trial at 199 of 388 partner sites.
Specializations
Solid Tumor Oncology
Focused on advanced or metastatic solid tumors across a broad spectrum of anatomical sites.
- Breast cancer (ER⁺/HER2‑, HER2‑positive, triple‑negative)
- Non‑small cell lung cancer (EGFR‑mutated, KRAS‑mutated, ALK‑positive)
- Renal cell carcinoma (clear‑cell, non‑clear‑cell)
- Gastro‑intestinal cancers (colorectal, gastric, biliary tract, pancreatic)
- Gynecologic malignancies (ovarian, endometrial, cervical, vulvar, anal)
- Rare solid tumors (mesothelioma, thyroid, salivary‑gland, neuroendocrine)
Research conducted at Hospital Vall d’Hebron and its Institute of Oncology, encompassing 30 clinical trials.
Hematologic Malignancies
Investigation of high‑risk hematologic cancers and related transplant complications.
- Acute myeloid leukemia (including IDH‑mutated and MRD‑positive disease)
- Myelodysplastic syndromes and myeloproliferative neoplasms
- Non‑Hodgkin lymphomas (follicular, mantle‑cell, diffuse large B‑cell, marginal‑zone)
- Chronic lymphocytic leukemia and small‑lymphocytic lymphoma
- Multiple myeloma (relapsed/refractory)
- Graft‑versus‑host disease (acute and chronic forms)
Clinical programs integrate cellular therapies and targeted agents within the Vall d’Hebron oncology network.
Autoimmune and Inflammatory Disorders
Targeted studies of systemic and organ‑specific autoimmunity.
- Systemic lupus erythematosus (including cutaneous and renal manifestations)
- Rheumatoid arthritis and psoriatic arthritis
- Inflammatory myopathies (dermatomyositis, immune‑mediated necrotizing myopathy)
- Vasculitis (ANCA‑associated, IgA nephropathy)
- Hidradenitis suppurativa
- Atopic dermatitis
Efforts emphasize biomarker‑driven therapeutics and disease‑modifying strategies.
Infectious Diseases
Clinical evaluation of therapies for chronic and opportunistic infections.
- Nontuberculous mycobacterial lung infection (MAC)
- Human immunodeficiency virus infection and related complications
- Hepatitis B and C chronic infection
- COVID‑19 and post‑acute sequelae
- Invasive fungal infections (aspergillosis, candidiasis)
- Mycobacterial tuberculosis
Studies are integrated with multidisciplinary infectious disease services at the affiliated sites.
Cardiometabolic and Organ Dysfunction
Research addressing cardiovascular risk, metabolic disease, and organ‑specific failure.
- Atherosclerotic cardiovascular disease (primary prevention and secondary care)
- Heart failure (reduced and preserved ejection fraction)
- Obesity and overweight with associated metabolic syndrome
- Type 2 diabetes mellitus and diabetic complications
- Chronic kidney disease (including transplant rejection)
- Chronic liver disease (cirrhosis, ACLF, hepatocellular carcinoma)
Collaborative trials leverage cardiology and nephrology expertise within the Barcelona research ecosystem.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
